Combinatorial Antibodies Against Stage-Related Melanoma Antigens

Inventor: Dorothee Herlyn

Tech ID: HD-96003

Description: B cell libraries were prepared from melanoma patients who had complete clinical responses after tumor cell vaccination. The libraries were expressed on the surfaces of filamentous phages, then phages binding preferentially to melanoma cells were isolated. These libraries recognize stage-related melanoma-associated antigens. The antibodies may be useful for diagnosis of melanoma and the antigens recognized by the antibodies may have potential for vaccines against melanoma.

Key Words: Diagnostic, therapeutic, immunoassay, cancer, vaccine, melanoma

Applications and Advantages: The antibodies may be useful for immunodiagnosis of melanoma and the antigens recognized by the antibodies may have potential for vaccines against melanoma.

Intellectual Property Status: U.S. and international patents are pending.

Licensing Opportunity: This technology is available for license for diagnosis or therapy of melanoma.

Contact:

Meryle J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org

Last updated: Nov. 99